Evogene Ltd EVGN
News
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
Evogene Reports Second Quarter and First Half 2026 Financial Results
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Evogene Schedules Second Quarter 2026 Financial Results Release
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
